Hussein Tawbi, MD, PhD, explains that for patients with melanoma without a BRAF mutation, first-line therapies primarily include immunotherapy-based (IO) checkpoint inhibitors, with PD-1 inhibitor combination therapies being the current standard of care.
Role of Single-Agent vs Dual IO Evolves in Metastatic Melanoma
November 3rd 2023The role of immunotherapy continues to evolve for the treatment of patients with skin cancer, now with physicians able to choose between the use of single-agent vs dual immunotherapy treatments. In 2 separate Case-Based Roundtable events led by Alan Tan, MD, and Douglas B. Johnson, MD, MSCI, physicians considered these options for a patient with metastatic melanoma.
Read More
Following Progression on ICIs Lifileucel Shows Anti-tumor Response in Advanced Mucosal Melanoma
October 21st 2023Results of from a subgroup of patients in the phase 2 C-144-01 study with advanced mucosal melanoma showed a clinically meaningful response to lifileucel after progression on immune checkpoint inhibitors.
Read More